[go: up one dir, main page]

MX9304579A - Derivados de 4-aza-5alfa-androstan-3-ona 17beta-substituidos, fluorados, proceso para su preparaciony composicion farmaceutica que los comprende. - Google Patents

Derivados de 4-aza-5alfa-androstan-3-ona 17beta-substituidos, fluorados, proceso para su preparaciony composicion farmaceutica que los comprende.

Info

Publication number
MX9304579A
MX9304579A MX9304579A MX9304579A MX9304579A MX 9304579 A MX9304579 A MX 9304579A MX 9304579 A MX9304579 A MX 9304579A MX 9304579 A MX9304579 A MX 9304579A MX 9304579 A MX9304579 A MX 9304579A
Authority
MX
Mexico
Prior art keywords
17beta
androstan
aza
preparation
derivatives
Prior art date
Application number
MX9304579A
Other languages
English (en)
Inventor
Achille Panzeri
Marcella Nesi
Enrico Di Salle
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Publication of MX9304579A publication Critical patent/MX9304579A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona a derivados de 4-aza-5alfa-androstan-3-ona 17beta-substituidos fluorados, a un proceso para su preparación, a composiciones farmacéuticas que los contienen, y al uso de los compuestos como inhibidores de la acción de andrógenos, por medio de la inhibición de la 5alfa-reductasa de la testosterona.
MX9304579A 1992-07-31 1993-07-29 Derivados de 4-aza-5alfa-androstan-3-ona 17beta-substituidos, fluorados, proceso para su preparaciony composicion farmaceutica que los comprende. MX9304579A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929216284A GB9216284D0 (en) 1992-07-31 1992-07-31 Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives

Publications (1)

Publication Number Publication Date
MX9304579A true MX9304579A (es) 1994-02-28

Family

ID=10719598

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304579A MX9304579A (es) 1992-07-31 1993-07-29 Derivados de 4-aza-5alfa-androstan-3-ona 17beta-substituidos, fluorados, proceso para su preparaciony composicion farmaceutica que los comprende.

Country Status (28)

Country Link
US (1) US5407939A (es)
EP (1) EP0607400B1 (es)
JP (1) JP3325025B2 (es)
KR (1) KR100311547B1 (es)
CN (1) CN1041096C (es)
AT (1) ATE159951T1 (es)
AU (1) AU660562B2 (es)
CA (1) CA2120343A1 (es)
CZ (1) CZ286240B6 (es)
DE (1) DE69315050T2 (es)
DK (1) DK0607400T3 (es)
ES (1) ES2110620T3 (es)
FI (1) FI113778B (es)
GB (1) GB9216284D0 (es)
GR (1) GR3025546T3 (es)
HU (2) HUT67043A (es)
IL (1) IL106520A (es)
MX (1) MX9304579A (es)
MY (1) MY109633A (es)
NO (1) NO305401B1 (es)
NZ (1) NZ254787A (es)
PH (1) PH29938A (es)
PL (1) PL178591B1 (es)
RU (1) RU2125061C1 (es)
TW (1) TW286319B (es)
UA (1) UA41291C2 (es)
WO (1) WO1994003475A1 (es)
ZA (1) ZA935481B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ258435A (en) * 1992-12-18 1997-05-26 Merck & Co Inc Prostatitis treatment; method using 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-l-en-3-ones
PT705272E (pt) * 1993-06-24 2002-07-31 Richter Gedeon Vegyeszet Novo processo para preparacao de derivados de 4-azaandrostano 17beta-substituido
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
CN1058499C (zh) * 1993-10-21 2000-11-15 麦克公司 １６－取代－４－氮杂－雄甾烷－５α－还原酶同工酶１抑制剂
GB9415178D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 4-azasteroids with side-chain fluoroketones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
IT1275594B1 (it) * 1995-07-21 1997-08-06 Pharmacia S P A Ora Pharmacia Epimeri del (22rs)-n-(1,1,1-trifluoro-2-fenilprop-2-il)-3-osso -4-aza-5alfa-androst-1-ene-17beta-carbossammide
GB9518858D0 (en) * 1995-09-14 1995-11-15 Pharmacia Spa Phenylsubstituted 4-azasteroid fluoroderivatives
GB9727522D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Process for preparing carboxamido-4-azasteroids
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
PL372920A1 (en) * 2002-03-13 2005-08-08 Merck & Co,Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
CA2530182A1 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
EP1641761A4 (en) * 2003-06-30 2008-05-14 Merck & Co Inc 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
AU2004259664B2 (en) * 2003-06-30 2009-05-28 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7696217B2 (en) * 2003-06-30 2010-04-13 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
WO2005025579A1 (en) 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
JP2007505120A (ja) * 2003-09-10 2007-03-08 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節因子としての１７−複素環式−４−アザステロイド誘導体。
EP1734964A4 (en) * 2004-04-08 2009-06-17 Merck & Co Inc 17-BETA-ACETAMIDE-4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS
CN102282133A (zh) * 2008-10-28 2011-12-14 生物马林药物股份有限公司 十氢-1h-茚并喹啉酮和十氢-3h-环戊并菲啶酮cyp17抑制剂
KR102541494B1 (ko) 2019-09-11 2023-06-08 주식회사 엘지화학 고흡수성 수지의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
GB9002922D0 (en) * 1990-02-09 1990-04-04 Erba Carlo Spa 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
AUPP930799A0 (en) * 1999-03-18 1999-04-15 University Of Sydney, The Optical planar waveguide device and method of its fabrication

Also Published As

Publication number Publication date
UA41291C2 (uk) 2001-09-17
DE69315050D1 (de) 1997-12-11
AU660562B2 (en) 1995-06-29
DE69315050T2 (de) 1998-03-05
CZ153893A3 (en) 1994-02-16
HU211238A9 (en) 1995-11-28
RU2125061C1 (ru) 1999-01-20
FI941424A7 (fi) 1994-05-27
HU9400914D0 (en) 1994-06-28
GR3025546T3 (en) 1998-03-31
CN1041096C (zh) 1998-12-09
EP0607400B1 (en) 1997-11-05
WO1994003475A1 (en) 1994-02-17
EP0607400A1 (en) 1994-07-27
FI941424A0 (fi) 1994-03-28
CZ286240B6 (cs) 2000-02-16
MY109633A (en) 1997-03-31
HK1011693A1 (en) 1999-07-16
FI113778B (fi) 2004-06-15
HUT67043A (en) 1995-01-30
ZA935481B (en) 1994-05-16
CN1085224A (zh) 1994-04-13
ES2110620T3 (es) 1998-02-16
IL106520A0 (en) 1993-11-15
JPH06511497A (ja) 1994-12-22
GB9216284D0 (en) 1992-09-16
NO941080D0 (no) 1994-03-24
US5407939A (en) 1995-04-18
IL106520A (en) 1997-11-20
CA2120343A1 (en) 1994-02-17
NZ254787A (en) 1995-11-27
AU4704893A (en) 1994-03-03
PH29938A (en) 1996-09-16
KR100311547B1 (ko) 2002-06-20
DK0607400T3 (da) 1998-01-26
NO305401B1 (no) 1999-05-25
ATE159951T1 (de) 1997-11-15
JP3325025B2 (ja) 2002-09-17
NO941080L (no) 1994-05-18
TW286319B (es) 1996-09-21
PL178591B1 (pl) 2000-05-31

Similar Documents

Publication Publication Date Title
MX9304579A (es) Derivados de 4-aza-5alfa-androstan-3-ona 17beta-substituidos, fluorados, proceso para su preparaciony composicion farmaceutica que los comprende.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
UY26199A1 (es) Nuevos derivados de benceno, un procedimiento para su preparación y las composiciones farmacéuticas que los contienen
MX9305769A (es) Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
ES2106029T3 (es) Composiciones que mejoran la penetracion a traves de la piel.
MX167801B (es) Inhibidor de la corrosion para combustibles liquids
MX9304581A (es) Desoxitaxoles y composiciones farmaceuticas que los contienen
AR023363A1 (es) Compuestos derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina, composicion y uso de los mismos
BR0113989A (pt) Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
ES2075437T3 (es) Nuevo derivado del acido cafeico, el oraposido, composicion cosmetica o farmaceutica, particularmente dermatologica que lo contiene.
ES2093645T3 (es) Nueva clase de compuestos que tienen un espectro variable de actividades para respuestas de tipo capsaicina, composiciones y usos de los mismos.
MX9202166A (es) Derivados de amidino fenil alanina, procedimiento para su preparacion su empleo y agentes que los con tienen en calidad de anticoagulantes.
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
BR9813468A (pt) Inibidores triazìnicos da angiogênese
BR9803887A (pt) Macrociclos.
AR005827A1 (es) Compuesto derivado de nucleosidos aciclicos, composicion farmaceutica que lo comprende, uso del mismo en la preparacion de un medicamento y su metodo de preparacion
ES2098505T3 (es) Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2063852T3 (es) Supresion de la sintesis y secrecion de la hormona paratiroide con derivados de vitamina d3.
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
ES2150461T3 (es) Derivados de amidinofenilalanina, proceso para su preparacion, su empleo y agentes que los contienen como anticoagulantes.
AR012546A1 (es) Utilizacion de al menos un compuesto seleccionado entre el grupo que comprende los sogaoles y los gingeroles para la preparacion de una composiciondesodorante, sogaol, extracto bruto y extracto purificado que contiene el sogaol y la composicion desodorante obtenida.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees